Osiris Therapeutics

Osiris Therapeutics, Inc. was an American company founded in March 1993 following the identification of mesenchymal stem cells (MSCs) by Dr. Arnold Caplan and colleagues at Case Western Reserve University in Cleveland, Ohio. Dr. Caplan contributed a license to certain technology and joined Kevin Kimberlin, James S. Burns, a biotech venture capitalist, and Peter Friedli, as lead investor, to launch Osiris, named after the Egyptian god of fertility, resurrection, and the afterlife. Early financing was provided by a number of entities, including Friedli Corporate Finance, Three Arch Bay Health Sciences Fund, and Spencer Trask & Co. By 1994, the state of Maryland provided a loan and equity investment to lure the company from Ohio in 1995.

Source: Wikipedia · CC BY-SA 4.0